article thumbnail

Valneva accelerates Lyme disease vaccine R&D project with Pfizer

pharmaphorum

This investigational multivalent protein subunit vaccine targets the outer surface protein A (OspA) of the bacterium Borrelia that causes the disease, an established mechanism of action for a Lyme disease vaccine.

Vaccine 119
article thumbnail

Lumen Bioscience’s LMN-201 secures FDA fast track status to treat CDI

Pharmaceutical Technology

An investigational orally delivered biologic drug, LMN-201 is a cocktail of four therapeutic proteins that act synergistically to neutralise the C difficile bacterium and the toxin. It is compatible with standard-of-care antibiotics.

Bacterium 130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Sanofi snaps up acne vaccine developer Origimm Bio

pharmaphorum

The French group said that ORI-001, a vaccine based on recombinant proteins from the Cutibacterium acnes (formerly Propionibacterium acnes ) bacterium that is often found in acne lesions, could be the first ever vaccine for the condition.

Vaccine 105
article thumbnail

Symvivo’s Oral COVID-19 Vaccine Enters Clinical Trials

XTalks

Graves explained the gene therapy platform delivers plasmid DNA that enables a patient’s own cells to produce therapeutic proteins that work to clear harmful virus particles from healthy tissues. The body should, therefore, produce an immune response against the Spike antigen to protect against SARS-CoV-2 infection.

article thumbnail

The Pharma Data - Untitled Article

The Pharma Data

Years of toil in the laboratory have revealed how a marine bacterium makes a potent anti-cancer molecule. The work solves a nearly 20-year riddle about how the marine bacterium makes the warhead that is unique to the salinosporamide molecule and opens the door to future biotechnology to manufacture new anti-cancer agents.

article thumbnail

Shot in the arm for Affinivax as it challenges Pfizer’s Prevnar

pharmaphorum

The shot also includes two “conserved” pneumococcal proteins – antigens that seem always to be present in the bacterium regardless of its serotype, so could potentially provide protection against an even broader range.

article thumbnail

GSK bolsters vaccines division with $3.3bn swoop on Affinivax

pharmaphorum

With ASP3772, GSK could offer a shot with broader coverage of pneumococcal serotypes than any of its rivals, and which also includes two “conserved” pneumococcal proteins – antigens that seem always to be present in the bacterium regardless of its serotype.

Vaccine 52